Lucas Moreno Martín-Retortillo I am a doctor specialized in paediatric cancer. I lead the Paediatric Oncology and Haematology Division of Vall d’Hebrón since 2019, with an outstanding team dedicated to providing the best care to our patients and families, and being national and international reference for numerous paediatric cancers. My goal is to improve cancer treatment so that no children and adolescents die of cancer, and that survivors can live a full life free of sequels Institutions of which they are part Head of group Childhood Cancer and Blood Disorders Vall Hebron Institut de Recerca Clinical Director Paediatric Oncology and Haematology Children's Hospital and Woman's Hospital LinkedIn Lucas Moreno Martín-Retortillo LinkedIn Institutions of which they are part Head of group Childhood Cancer and Blood Disorders Vall Hebron Institut de Recerca Clinical Director Paediatric Oncology and Haematology Children's Hospital and Woman's Hospital I am a doctor specialized in paediatric cancer. I lead the Paediatric Oncology and Haematology Division of Vall d’Hebrón since 2019, with an outstanding team dedicated to providing the best care to our patients and families, and being national and international reference for numerous paediatric cancers. My goal is to improve cancer treatment so that no children and adolescents die of cancer, and that survivors can live a full life free of sequels
Dr. Lucas Moreno just moved to Barcelona to lead the Paediatric Oncology & Haematology Division at Vall d'Hebron Hospital. He has devoted his career to childhood cancer drug development. His main research interest is in neuroblastoma, one of the most aggressive forms of childhood cancer. After returning from London where he worked at the Royal Marsden Hospital from 2008 to 2012, he created and led the Clinical Trials Unit at Hospital Niño Jesús (Madrid) that became a leading trials unit for paediatric drug development nationally and internationally. He is a key opinion leader in neuroblastoma and drug development in Europe and works for international networks such as SIOPEN (siopen.net) and ITCC (itcc-consortium.org). He leads the BEACON-Neuroblastoma trial open in 10 European countries for relapsed & refractory neuroblastoma. He has been principal investigator of more than 30 clinical trials and has co-authored more than 60 international publications in the field. He provides second opinion consultations for children and adolescents with relapsed/refractory cancers nationally and internationally to facilitate access to early clinical trials and novel agents. He is a keen supporter of incorporating the patient/parents voice into research and clinical practice and has started several projects on quality of life, quality of care, late effects and patient reported outcomes. His favourite conference of the year is the Solving Kids’ Cancer Parent conference because of the excellent interaction between researchers, clinicians and parents.
Projects International integrated analysis to identify markers of poor survival in high-risk neuroblastoma IP: Lucas Moreno Martín-Retortillo Collaborators: Andrea Vilaplana Blanes, Mariona Morell Daniel Funding agency: Solving Kids’ Cancer Funding: 131766.91 Reference: SKC/AEFRM/2020/MORENO Duration: 02/11/2020 - 01/11/2023 Quatsomes as a novel nanomaterial platform for nucleic acids delivery IP: Miguel Segura Ginard Collaborators: Aroa Soriano Fernández, Lucas Moreno Martín-Retortillo Funding agency: Instituto de Salud Carlos III Funding: 83600 Reference: DTS20/00018 Duration: 01/01/2021 - 31/12/2022 Programa de fellowship para formación en Hematología y Oncología Pediátrica Hospital Vall d’Hebrón IP: Lucas Moreno Martín-Retortillo Collaborators: Genoveva Arqueros Sánchez Funding agency: Asociación padres niños oncológicos Aragón ASPANOA Funding: 30000 Reference: ASPANOA/PROJ-BECA/2019/FERNANDEZ Duration: 01/11/2019 - 30/04/2021 Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4
